Early response of σ-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: An in vitro study in glioma cells

Journal of Nuclear Medicine

Volumn 47, Issue 9, 2006, Pages 1538-1545

  Van Waarde, Aren ^a   Been, Lukas B ^a   Ishiwata, Kiichi ^b   Dierckx, Rudi A ^a   Elsinga, Philip H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

receptor ligands; 3 deoxy 3 fluorothymidine; 5 fluorouracil; Cisplatin; Doxorubicin

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE C 11; ADENOSINE TRIPHOSPHATE; CARBON 11; CHOLINE C 11; CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FLURADECYL; IRON SA 5845 F 18; METHIONINE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOISOTOPE; SIGMA OPIATE RECEPTOR;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL CYCLE S PHASE; CELL MEMBRANE; CELL METABOLISM; CELL VIABILITY; CONTROLLED STUDY; GLIOMA CELL; IN VITRO STUDY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RAT STRAIN; ANIMAL; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECT; GLIOMA; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PATHOLOGY; PROTEIN BINDING; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; GLIOMA; METABOLIC CLEARANCE RATE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; RECEPTORS, SIGMA; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 33750584289     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol. 1999;175:356-373.
2. 11C-choline positron emission tomography. Eur Urol. 2002;42:18-23.
3. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409-1415.
4. Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med. 2001;15:471-486.
5. Lorenzen J, de Wit M, Buchert R, Igel B, Bohuslavizki KH. Granulation tissue: pitfall in therapy control with F-18-FDG PET after chemotherapy. Nuklearmedizin. 1999;38:333-336.
6. Kubota K, Yamada K, Fukada H, et al. Tumor detection with carbon-11-labelled amino acids. Eur J Nucl Med. 1984;9:136-140.
7. Shields AF, Lim K, Grierson J, Link J, Krohn KA. Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med. 1990;31:337-342.
8. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
9. Shinoura N, Nishijima M, Hara T, et al. Brain tumors: detection with C-11 choline PET. Radiology. 1997;202:497-503.
10. Wheeler KT, Wang LM, Wallen CA, et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer. 2000;82:1223-1232.
11. Hayashi T, Su TP. The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: implication for drug abuse. Life Sci. 2005;77:1612-1624.
12. Sato K, Kameyama M, Ishiwata K, Katakura R, Yoshimoto T. Metabolic changes of glioma following chemotherapy: an experimental study using four PET tracers. J Neurooncol. 1992;14:81-89.
13. Schaider H, Haberkorn U, Berger MR, Oberdorfer F, Morr I, Van Kaick G. Application of α-aminoisobutyric acid, L-methionine, thymidine and 2-fluoro-2-deoxy-D-glucose to monitor effects of chemotherapy in a human colon carcinoma cell line. Eur J Nucl Med. 1996;23:55-60.
14. Takeda N, Diksic M, Yamamoto YL. The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy. Cancer. 1996;77:1167-1179.
15. Steele RJ, Brown M, Eremin O. Characterisation of macrophages infiltrating human mammary carcinomas. Br J Cancer. 1985;51:135-138.
16. Whitford P, Mallon EA, George WD, Campbell AM. Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br J Cancer. 1990;62:971-975.
17. Reedijk J, Lohman PHM. Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Week Sci. 1985;7:173-180.
18. Zunino F, Capranico G. DNA topoisomerase-II as the primary target of antitumor anthracyclines. Anticancer Drug Des. 1990;5:307-317.
19. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48:381-395.
20. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H. Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol. 1999;125:481-486.
21. 11C-SA4503: a feasibility study. J Nucl Med. 2004;45:1939-1945.
22. van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med. 2006;47:150-154.
23. 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]- 4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol. 2003;30:273-284.
24. Schott B, Robert J. Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells. Biochem Pharmacol. 1989;38:167-172.
25. Mineura K, Kowada M. Enhancement of 5-fluorouracil cytotoxicity by cisplatin in brain tumour cell lines. Cell Biol Int. 1996;20:355-357.
26. Mares V, Giordano PA, Mazzini G, et al. Influence of cis- dichlorodiamineplatinum on glioma cell morphology and cell cycle kinetics in tissue culture. Histochem J. 1987;19:187-194.
27. Fornari FA Jr, Jarvis DW, Grant S, et al. Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem Pharmacol. 1996;51:931-940.
28. Yoshikawa R, Kusunoki M, Yanagi H, et al. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 2001;61:1029-1037.
29. Davoodpour P, Bergstrom M, Landstrom M. Effects of 2-methoxyestradiol on proliferation, apoptosis and PET-tracer uptake in human prostate cancer cell aggregates. Nucl Med Biol. 2004;31:867-874.
30. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791-3798.
31. Carnochan P, Brooks R. Radiolabelled 5-iodo-2′-deoxyuridine: a promising alternative to [F-18]-2-fluoro-2-deoxy-D-glucose for PET studies of early response to anticancer treatment. Nucl Med Biol. 1999;26:667-672.
32. Dittmann H, Dohmen BM, Kehlbach R, et al. Early changes in [F-18]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002;29:1462-1469.
33. Fleischmannova V, Schmeer A, Drobnik J, Lodin Z, Mares V. The influence of drugs with a cytostatic action on the growth and differentiation of glioma cells in tissue culture [abstract]. Physiol Bohemoslov. 1982;31:441.
34. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414-419.
35. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
36. Scanlon KJ, Safirstein RL, Thies H, Gross RB, Waxman S, Guttenplan JB. Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res. 1983;43:4211-4215.
37. Mineura K, Sasajima T, Sasajima H, Kowada M. Inhibition of methionine uptake by cis-diamminedichloroplatinum (II) in experimental brain tumors. Int J Cancer. 1996;67:681-683.
38. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol. 1993;32:167-172.
39. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281-287.
40. Kong XB, ZhuQY,Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36:808-818.